TargetMol

TISCH

Product Code:
 
TAR-T28979
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28979-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28979-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28979-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
TISCH is a potent and selective iodinated ligand for CNS D1 dopamine receptor.
CAS:
131615-52-6
Formula:
C17H17ClINO
Molecular Weight:
413.68
Purity:
0.98
SMILES:
CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1cccc(I)c1

References

1. Smith CB, Phillips T, Smith TJ. Using the New ASCO Clinical Practice Guideline for Palliative Care Concurrent With Oncology Care Using the TEAM Approach. Am Soc Clin Oncol Educ Book. 2017;37:714-723. doi: 10.14694/EDBK_175474. PubMed PMID: 28561696. 2. Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352-z. [Epub ahead of print] PubMed PMID: 28555325. 3. Germain D. Toward the identification and the targeting of key players of the mitochondrial unfolded protein response (UPR(mt)) in cancer. J Bioenerg Biomembr. 2017 May 29. doi: 10.1007/s10863-017-9716-x. [Epub ahead of print] PubMed PMID: 28555290. 4. Molotkov A, Mazot P, Brewer JR, Cinalli RM, Soriano P. Distinct Requirements for FGFR1 and FGFR2 in Primitive Endoderm Development and Exit from Pluripotency. Dev Cell. 2017 May 23. pii: S1534-5807(17)30386-6. doi: 10.1016/j.devcel.2017.05.004. [Epub ahead of print] PubMed PMID: 28552557.